These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33140116)

  • 21. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats.
    Ishikawa K; Ohba T; Tanaka N; Iqbal M; Okamura Y; Okamura H
    Endocr J; 2003 Oct; 50(5):515-25. PubMed ID: 14614207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.
    Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R
    Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of bevacizumab and cabergoline in the treatment of ovarian hyperstimulation syndrome in a rat model.
    Engin-Ustun Y; Yılmaz S; Timur H; Ustun Y; Moraloglu O; Deveer R; Yılmaz N
    Gynecol Endocrinol; 2013 Sep; 29(9):851-4. PubMed ID: 23862585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of formoterol on the serum, peritoneal VEGF, MDA, and VEGF levels in the ovaries and endometrium of rats with OHSS.
    Inal HA; Ozturk Inal ZH; Yilmaz N; Timur H; Oruc AS; Kalem MN; Han O
    Clin Exp Obstet Gynecol; 2017; 44(1):122-128. PubMed ID: 29714880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication.
    Ohba T; Ujioka T; Ishikawa K; Tanaka N; Okamura H
    Mol Cell Endocrinol; 2003 Apr; 202(1-2):47-52. PubMed ID: 12770729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability.
    Gómez R; Simón C; Remohí J; Pellicer A
    Biol Reprod; 2003 Jun; 68(6):2164-71. PubMed ID: 12606463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
    Gómez R; Lima I; Simón C; Pellicer A
    Reproduction; 2004 Apr; 127(4):483-9. PubMed ID: 15047939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
    Gómez R; Simón C; Remohí J; Pellicer A
    Endocrinology; 2002 Nov; 143(11):4339-48. PubMed ID: 12399430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
    Kosmas IP; Kitsou C; Lazaros L; Markoula S; Peschos D; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos A; Galani V; Georgiou I
    Gynecol Endocrinol; 2015; 31(9):702-7. PubMed ID: 26172931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
    Rizk B; Aboulghar M; Smitz J; Ron-El R
    Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats.
    Kitajima Y; Endo T; Manase K; Nishikawa A; Shibuya M; Kudo R
    Fertil Steril; 2004 Mar; 81 Suppl 1():842-9. PubMed ID: 15019818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of kisspeptin-54 on ovarian levels of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in an experimental model of ovarian hyperstimulation syndrome (OHSS).
    Birinci H; Vatansever HS; Yüncü M
    Reprod Fertil Dev; 2021 Nov; 33(16):799-809. PubMed ID: 34610858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
    Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
    Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Ovarian Hyperstimulation Syndrome in a Mouse Model by Cannabidiol, an Angiogenesis Pathway Inhibitor.
    Tahermanesh K; Hakimpour S; Govahi A; Keyhanfar F; Kashi AM; Chaichian S; Shahriyaripour R; Ajdary M
    Biomed Res Int; 2022; 2022():1111777. PubMed ID: 36588534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium gluconate infusion is not as effective as dopamine agonists in preventing ovarian hyperstimulation syndrome.
    Turktekin N; Karakus C; Ozyurt R
    Eur Rev Med Pharmacol Sci; 2022 Feb; 26(4):1248-1254. PubMed ID: 35253181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of ondansetron for preventing of ovarian hyperstimulation syndrome: in an experimental rat model.
    Bakırcı Ş; Sağsöz N; Devrim T; Şahin Y; Bulanık M; Gözüyukarı H
    Gynecol Endocrinol; 2022 Dec; 38(12):1093-1096. PubMed ID: 36579847
    [No Abstract]   [Full Text] [Related]  

  • 38. Investigation of short- and long-term effects of ovarian hyperstimulation syndrome on ovarian reserve: an experimental study.
    Pala S; Atilgan R; Ozkan ZS; Akpolat N; Ilhan N; Sapmaz E
    Clin Exp Obstet Gynecol; 2015; 42(1):95-100. PubMed ID: 25864291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study.
    Kitsou C; Kosmas I; Lazaros L; Tzallas C; Tinelli A; Mynbaev O; Prapas N; Prapas I; Dalkalitsis A; Georgiou I
    Gynecol Endocrinol; 2016 Nov; 32(11):886-890. PubMed ID: 27223459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice.
    Chuderland D; Ben-Ami I; Kaplan-Kraicer R; Grossman H; Ron-El R; Shalgi R
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E258-66. PubMed ID: 23295464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.